Robert Sidney Rosenson

Robert Sidney Rosenson

Auto-generated profile, based on publicly available information

Robert Sidney Rosenson

Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
RRRobert S. Rosenson
Robert S. Rosenson
HBH. Bryan Brewer
H. Bryan Brewer
WDW. Sean Davidson
W. Sean Davidson
ZFZahi A. Fayad
Zahi A. Fayad
VFValentin Fuster
Valentin Fuster
LYLaurent Yvan-Charvet
Laurent Yvan-Charvet

1 September 2015 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
RRRobert S. Rosenson
Robert S. Rosenson
HBH. Bryan Brewer
H. Bryan Brewer
BABenjamin J. Ansell
Benjamin J. Ansell
PBPhilip Barter
Philip Barter
MCM. John Chapman
M. John Chapman
NWNancy R. Webb
Nancy R. Webb

1 March 2011 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
RRRobert S Rosenson
Robert S Rosenson
HBH Bryan Brewer
H Bryan Brewer
MCM John Chapman
M John Chapman
SFSergio Fazio
Sergio Fazio
MHM Mahmood Hussain
M Mahmood Hussain
ESErnst J Schaefer
Ernst J Schaefer
BACKGROUND: A growing body of evidence from epidemiological data, animal studies, and clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin-treated, high-risk patients. For more than 3 decades, HDL cholesterol has been employed as the principal clinical measure of HDL and cardiovascular risk associated with low HDL-cholesterol concentrations. The physicochemical and functional heterogeneity of HDL present important challenges to investigators in the cardiovascular field who are seeking to identify more effective laboratory and clinical methods to develop a measurement method to quantify HDL that has predictive value in assessing cardiovascular risk.CONTENT: In this report, we critically evaluate the diverse physical and chemical methods that have been employed to characterize plasma HDL. To facilitate future characterization of HDL subfractions, we propose the development of a new nomenclature based on physical properties for the subfractions of HDL that includes very large HDL particles (VL-HDL), large HDL particles (L-HDL), medium HDL particles (M-HDL), small HDL particles (S-HDL), and very-small HDL particles (VS-HDL). This nomenclature also includes an entry for the pre-β-1 HDL subclass that participates in macrophage cholesterol efflux.SUMMARY: We anticipate that adoption of a uniform nomenclature system for HDL subfractions that integrates terminology from several methods will enhance our ability not only to compare findings with different approaches for HDL fractionation, but also to assess the clinical effects of different agents that modulate HDL particle structure, metabolism, and function, and in turn, cardiovascular risk prediction within these HDL subfractions.

1 May 2014 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
RRRobert S. Rosenson
Robert S. Rosenson
SBSteven K. Baker
Steven K. Baker
TJTerry A. Jacobson
Terry A. Jacobson
SKStephen L. Kopecky
Stephen L. Kopecky
BPBeth A. Parker
Beth A. Parker

1 December 2014 in JACC
Verified
Journal Article
Closed access
RRRobert S. Rosenson
Robert S. Rosenson
MDMichael H. Davidson
Michael H. Davidson
BHBenjamin J. Hirsh
Benjamin J. Hirsh
SKSekar Kathiresan
Sekar Kathiresan
DGDaniel Gaudet
Daniel Gaudet

1 July 2018 in JACC
Verified
Journal Article
Closed access
RRRobert S. Rosenson
Robert S. Rosenson
RHRobert A. Hegele
Robert A. Hegele
SFSergio Fazio
Sergio Fazio
CCChristopher P. Cannon
Christopher P. Cannon